MetaCap

Corbus Pharmaceuticals (CRBP) vs Intercure (INCR)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Intercure (INCR) has outperformed Corbus Pharmaceuticals (CRBP) over the past year, losing 50.6% versus a loss of 82.8%. Over five years, INCR leads with a -90.9% price change compared with -92.2% for CRBP. Corbus Pharmaceuticals is the larger company by market cap ($42.4 million vs $42.0 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CRBP-82.85%INCR-50.57%
+15%-36%-88%
Nov 21, 20251 yearNov 20, 2026
CRBP-92.63%INCR-91.77%
+129%+13%-103%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CRBP versus INCR key metrics
MetricCRBPINCR
Share price$2.06$3.24
Market cap$42.45M$42.03M
1-day change-15.40%-7.69%
YTD return-74.69%-28.79%
1-year return-82.85%-50.57%
5-year return-92.23%-90.87%
EPS (TTM)$-6.04$-0.95
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-78.54M—
52-week high$12.88$7.55
52-week low$2.01$3.12
Distance from 52-week high-84.01%-57.09%
Analyst consensusstrong_buy—
Avg. price target upside+1551.94%—
Average volume1.11M15.93K
Shares outstanding20.61M12.97M
Employees36285
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • INCR has outperformed CRBP by 32.3 percentage points over the past year.

About Corbus Pharmaceuticals

CRBP stock →

Corbus Pharmaceuticals Holdings, Inc., a clinical stage company, develops and commercializes therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E; and CRB-913, a peripherally restricted cannabinoid type-1 receptor inverse agonist for the treatment of obesity.

Health Care · Biotechnology: Pharmaceutical Preparations · 36 employees

About Intercure

INCR stock →

InterCure Ltd., together with its subsidiaries, engages in the production, manufacturing, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil.

Health Care · Biotechnology: Pharmaceutical Preparations · 285 employees

CRBP vs INCR FAQ

Which is bigger, Corbus Pharmaceuticals or Intercure?

Corbus Pharmaceuticals (CRBP) is larger, with a market capitalization of $42.45M compared with $42.03M for Intercure (INCR).

Which stock has performed better over the past year, CRBP or INCR?

INCR returned -50.57% over the past 12 months, compared with -82.85% for CRBP (price return, excluding dividends). Past performance does not predict future results.

Are Corbus Pharmaceuticals and Intercure in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons